Table 3.
Anti-HIV activity and toxicity of C-α and β-PAA
| PAA | Inhibition (%) | Toxicity (%) | %Inhibition/ %Toxicity | ED50* (μM) | CC50** (μM) | SI*** |
|---|---|---|---|---|---|---|
| FRF 4c | 67 ± 5 | 29 ± 2 | >2.3 | 869 | >1000 | >1.2 |
| FFK 1b | 80 ± 2 | 37 ± 8 | >2.2 | 254 | id | >4 |
| FFR 2b | 83 ± 4 | 38 ± 2 | >2.2 | 130 | id | >8 |
| RFF 3b | 96 ± 1 | 36 ± 3 | >2.7 | 85 | id | >12 |
| FRF 4b | 92 ± 4 | 18 ± 7 | >5.1 | 56 | id | >18 |
| FKR 5b | 85 ± 2 | 29 ± 6 | >2.9 | 219 | id | >4.5 |
| FRR 6b | 95 ± 1 | 53 ± 5 | >1.8 | 60 | id | >17 |
| RRF 7b | 95 ± 1 | 36 ± 4 | >2.6 | 95 | id | >10.5 |
*ED50: Effective Dose. Dose of PAA required to inhibit 50% of the viral replication.
**CC50: Cytotoxic Concentration. Concentration of PAA required to reduce the cell number by 50%.
***SI: Selectivity Index (CC50/ED50).